TCE2 Stock Overview
A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Celldex Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.70 |
| 52 Week High | US$41.00 |
| 52 Week Low | US$13.20 |
| Beta | 1.39 |
| 1 Month Change | 15.97% |
| 3 Month Change | -25.45% |
| 1 Year Change | -55.82% |
| 3 Year Change | -34.82% |
| 5 Year Change | 687.74% |
| Change since IPO | -69.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| TCE2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.7% | 1.3% | 2.4% |
| 1Y | -55.8% | -12.0% | 13.2% |
Return vs Industry: TCE2 underperformed the German Biotechs industry which returned -12.2% over the past year.
Return vs Market: TCE2 underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| TCE2 volatility | |
|---|---|
| TCE2 Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: TCE2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TCE2's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 186 | Anthony Marucci | www.celldex.com |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
Celldex Therapeutics, Inc. Fundamentals Summary
| TCE2 fundamental statistics | |
|---|---|
| Market cap | €1.12b |
| Earnings (TTM) | -€140.62m |
| Revenue (TTM) | €6.25m |
184.6x
P/S Ratio-8.2x
P/E RatioIs TCE2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCE2 income statement (TTM) | |
|---|---|
| Revenue | US$7.02m |
| Cost of Revenue | US$163.55m |
| Gross Profit | -US$156.53m |
| Other Expenses | US$1.33m |
| Earnings | -US$157.86m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.38 |
| Gross Margin | -2,229.77% |
| Net Profit Margin | -2,248.76% |
| Debt/Equity Ratio | 0% |
How did TCE2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 05:29 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celldex Therapeutics, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | Brean Capital |
| Edward Nash | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |